ALB and non-small cell lung carcinoma: In addition, several authors have highlighted the adoption of albumin nanoparticles for the loading and the targeted delivery of Paclitaxel, a chemotherapeutic drug widely used to treat various types of cancer: in a Phase III clinical trial (n° NCT01620190), 503 patients with advanced, previously treated non-small cell lung cancer were randomly assigned to two different groups: 252 patients received albumin NPs–Paclitaxel on days 1, 8, and 15 at a dose of 100 mg/m2, while 251 patients received Docetaxel (a commonly administered formulation) at a dose of 60 mg/m2 on day 1 of a 21-day cycle.